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Objectives
The incidence of sexually transmitted infections (STIs) and HIV infection remains high in gay,
bisexual, and other men who have sex with men (MSM) in the UK, and sexualized drug use
(“chemsex”) and injecting drug use (“slamsex”) may play a part in this. We aimed to characterize
HIV-positive MSM engaging in chemsex/slamsex and to assess the associations with self-reported
STI diagnoses and sexual behaviours.
Methods
Data from a 2014 survey of people attending HIV clinics in England and Wales were linked to
clinical data from national HIV surveillance records and weighted to be nationally representative.
Multivariable logistic regression assessed the associations of chemsex and slamsex with self-
reported unprotected anal intercourse (UAI), serodiscordant UAI (sdUAI) (i.e. UAI with an HIV-
negative or unknown HIV status partner), sdUAI with a detectable viral load (>50 HIV-1 RNA
copies/mL), hepatitis C, and bacterial STIs.
Results
In the previous year, 29.5% of 392 sexually active participants engaged in chemsex, and 10.1% in
slamsex. Chemsex was significantly associated with increased odds of UAI [adjusted odds ratio
(AOR) 5.73; P < 0.001], sdUAI (AOR 2.34; P < 0.05), sdUAI with a detectable viral load (AOR 3.86;
P < 0.01), hepatitis C (AOR 6.58; P < 0.01), and bacterial STI diagnosis (AOR 2.65; P < 0.01).
Slamsex was associated with increased odds of UAI (AOR 6.11; P < 0.05), hepatitis C (AOR 9.39;
P < 0.001), and bacterial STI diagnosis (AOR 6.11; P < 0.001).
Conclusions
Three in ten sexually active HIV-positive MSM engaged in chemsex in the past year, which was
positively associated with self-reported depression/anxiety, smoking, nonsexual drug use, risky
sexual behaviours, STIs, and hepatitis C. Chemsex may therefore play a role in the ongoing HIV
and STI epidemics in the UK.
Keywords: hepatitis C, HIV transmission, men who have sex with men, recreational drugs, sexually
transmitted infections
Accepted 23 October 2017
Introduction
In 2015, there were over 435 000 new diagnoses of sexu-
ally transmitted infections (STIs) in England, and gay,
bisexual and other men who have sex with men (MSM)
were one of the most heavily impacted groups [1]. From
2012 to 2015, STI diagnoses in MSM rose sharply, with
gonorrhoea increasing by 105%, syphilis by 95%, and
chlamydia by 52% [1]. Sexually transmitted enteric
infections in MSM have also increased, with diagnoses of
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non-travel-associated Shigella flexneri 2a among men
increasing by 30% from 2014 to 2015, while diagnoses in
women remained stable [2]. Furthermore, new HIV diag-
noses in MSM rose to 3360 in 2014 [3], and modelling stud-
ies suggest that HIV incidence among MSM is increasing in
the UK [4]. Sexual transmission of hepatitis C virus (HCV) is
also ongoing in HIV-positive MSM [5]. Several factors are
likely to have contributed to the rise in infections in MSM,
one of which may be sexualized drug use.
Sexualised drug use, often called ‘chemsex’ or ‘party
and play’, is the practice of intentionally using drugs
before or during sex to increase both sexual pleasure
and arousal, and is practised mainly by gay, bisexual
and other MSM [6–8]. In the UK, the most common
chemsex drugs are crystal methamphetamine, gamma-
hydroxybutyric acid/gamma-butyrolactone (GHB/GBL),
and mephedrone (MCAT), with ketamine also used to
facilitate sex [7]. As a consequence of the prolonged
nature of chemsex sessions, which often involve mucos-
ally traumatic and condomless sex, there is an increased
risk of transmission of HIV, HCV and other STIs [9–12].
Chemsex drugs can also be injected, in a behaviour
called ‘slamming’, or ‘slamsex’, although this practice is
rare with GHB/GBL. Slamsex brings with it additional
risks of HIV and HCV infection if needles or other
injecting equipment is shared.
Previous work in the UK has shown that, among HIV-
positive MSM, recreational drug use, regardless of the
sexual context, is associated with condomless sex,
including with partners of unknown or HIV-negative
status, creating the possibility for HIV transmission
[13,14]. Drug use has also been linked to outbreaks of
Shigella flexneri 3a among MSM in London [15] and an
increased incidence of bacterial STIs and hepatitis C
[12,16–18]. Reports from urban centres such as London
and Bristol suggest that chemsex is increasing in popu-
larity [6,8,19,20], is more common among HIV-positive
than HIV-negative MSM [7,8,13,16], and may be linked
to HIV transmission [9,13,21–23].
Despite these concerns, quantitative data on chemsex
and its associated risks are sparse [8,13]. Indeed, a recent
editorial in the British Medical Journal called for chem-
sex to become a national public health priority in view of
the risk of HIV and STI transmission, while highlighting
the fact that a lack of quantitative data on chemsex and
slamsex is limiting the efforts of clinicians and policy
makers [24]. To address this gap, we aimed to quantify
the national prevalence of chemsex and slamsex among
HIV-positive MSM in the UK, characterize the popula-
tions involved, and explore associations with sexual risk
behaviours, hepatitis C, and bacterial STI diagnoses.
Methods
Study design and data collection
Positive Voices is a cross-sectional survey of people liv-
ing with HIV in the UK. Full details of the study and
recruitment methods have been presented previously [25].
Briefly, adults (aged ≥18 years) attending one of 30
National Health Service (NHS) HIV clinics in England and
Wales were selected to participate, using the national
cohort of persons diagnosed with HIV infection receiving
care held at Public Health England (PHE) as a national
sampling frame. Data were collected anonymously using
a web-based computer-assisted self-interview from May
to November 2014.
Data processing
Using an anonymous individual identifier, survey
responses were linked to clinical and demographic records
in the national cohort of persons in HIV care [26]. Linking
the two databases allowed us to incorporate clinical data
on participant viral loads at clinic visits in the last year
into our study. Of the 392 sexually active MSM, clinical
data on viral loads were available for 361 (92.1%).
Survey data were weighted by standardization based
on the age and risk group distributions in the 2014 clini-
cal data set of the national cohort of persons in HIV care
[26]. In this way, the data presented here were made to
be representative of the entire population of people with
HIV infection accessing care in the UK. Sampling weights
were subsequently applied to account for the unequal
sampling probability at different participating clinics.
Assessment of drug use for sexual pleasure
Participants were asked to report on the use of crystal
methamphetamine, GHB/GBL, ketamine, and mephedrone
before or during sexual encounters in the past year. The
slang/street names for all drugs were included in the
questionnaire. Chemsex was defined as the use of one or
more of these drugs in a sexual context using any route.
Participants who specifically reported injecting any of the
chemsex drugs for sexual purposes were classified as
having engaged in slamsex and were considered as a sub-
set of chemsex users. Comparators were sexually active
MSM who did not engage in the behaviour.
Sexual behaviours and STIs
Self-reported data were collected on condom use, number
of sexual partners, partner type (regular or casual), and
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HIV status of sexual partners over the previous year.
Unprotected anal intercourse (UAI) was defined as anal
sex without a condom with any partner in the previous
year. Serodiscordant UAI (sdUAI) was defined as having
UAI with a partner of unknown or HIV-negative status.
Participants were deemed to have engaged in sdUAI with
a detectable viral load if in the previous year they had
had sdUAI and had at least one viral load recorded >50
HIV-1 RNA copies/mL. The categories of sexual behaviour
were not mutually exclusive and comparators were sexu-
ally active MSM who did not engage in the behaviour.
We defined participants as having been diagnosed with
an STI in the previous year if they reported a new diag-
nosis of chlamydia, gonorrhoea or syphilis in the previ-
ous year. If a person was diagnosed with two or more
STIs in the previous year then he was classed as having
had multiple STIs. Participants also reported whether they
had ever been diagnosed with hepatitis C.
Assessment of other variables
Information on age, country of birth, educational attain-
ment, employment status, housing status, religion, rela-
tionship status, diagnosed depression/anxiety, smoking
status, frequency of binge drinking (consuming six or
more units of alcohol if female and eight or more if male
in one session), illicit drug use, antiretroviral therapy
(ART) status, and year of HIV diagnosis was self-reported
in the survey. Categorical variables were created: age was
categorized as 18–34, 35–44, 45–54, and ≥55 years;
region of birth (UK, rest of Europe, Africa and other) was
created based on country of birth; nonsexual recreational
drug use was assessed by asking participants to indicate
from a list which recreational drugs they had taken in
the last year, coding participants who indicated having
taken one or more of the drugs as drug users, but exclud-
ing participants who reported only taking drugs before
or during sex; time since HIV diagnosis was calculated
as the difference between self-reported year of diagno-
sis and the year of survey completion (2014 for all par-
ticipants), and categorized as <2 years since diagnosis,
2–5 years since diagnosis, 6–10 years since diagnosis,
and ≥11 years since diagnosis.
Statistical analyses
All analyses and data cleaning were conducted in STATA/
MP 14.1 (StataCorp MP College Station, Texas, USA) and
missing data were assumed to be missing at random. The
weighted prevalence of chemsex and slamsex in sexually
active MSM was calculated overall, and for each chemsex
drug, with 95% confidence intervals (CIs). We tested if
chemsex and slamsex use differed by various socio-
demographic factors and health indicators using a
two-tailed v2 statistic, and considered differences to be
statistically significant at P < 0.05.
We assessed the associations of chemsex and slamsex
with UAI, sdUAI, sdUAI with a detectable viral load, and
diagnosis with bacterial STIs and hepatitis C using multi-
variable logistic regression. The associations between
chemsex/slamsex and number of casual sexual partners
were assessed using multivariable linear regression. All
multivariable models were constructed using directed
acyclic graphs (Figure S1) to determine which variables
to control for [27–31]. All regressions were assessed for
statistical significance with an alpha level of 5%.
Study population
A total of 4350 invitations were issued to participating
clinics, representing approximately 20% of the adult
HIV-infected population of each clinic. Of these, 3045
(70%) were handed out and 777 responses were received
(response rate of 25.6% from all those invited to partici-
pate and 39.0% among MSM). Of the 777 respondents,
532 were classed as MSM based on self-identifying their
gender as male and reporting either having had sex with
a man in the last year or that their sexual orientation
was gay or bisexual. After exclusion of participants who
were not sexually active in the last year (i.e. those who
did not report having had sex with a man in the last
year), the study population consisted of 392 sexually
active MSM. The total weighted population of sexually
active HIV-positive MSM in the study was 24 956.
Ethics
Positive Voices was funded by the National Institute for
Health Research and was reviewed by the London Harrow
NHS Research Ethics Committee (Project ID 13/LO/0279).
The funder had no role in the design, analysis or inter-
pretation of the study.
Results
Of the 392 MSM who were sexually active in the past
year, 102 (29.5%) reported engaging in chemsex and 34
(10.1%) in slamsex (Figure 1). Among chemsex users, the
most commonly used drugs were GHB/GBL (71.6%; 68 of
102) and mephedrone (71.4%; 76 of 102). The most com-
monly used drugs for slamsex were crystal metham-
phetamine (69.2%; 24 of 34) and mephedrone (64.2%; 22
of 34). Among all MSM, 54.2% (275 of 532) had used
© 2018 The Authors.
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drugs in the last year and 42.5% (201 of 532) had used
drugs in the last 4 weeks. Detailed drug use for all MSM
is presented in Figure S2.
Chemsex was more common among participants aged
18–44 years, those living in London, those diagnosed
with depression or anxiety at some point in their lives,
current cigarette smokers, and those who reported non-
sexual recreational drug use (Table 1). There were no dif-
ferences by region of birth, education level, employment
status, relationship status, binge drinking frequency, ART
status, or time since HIV diagnosis. Slamsex was more
common among participants who lived in London and
were on ART, but no other differences were found
(Table 2).
Three-quarters of participants reported UAI (72.3%;
278 of 386), with two-thirds reporting sdUAI (35.0%; 132
of 371), and one in ten reporting sdUAI with a detectable
viral load (9.8%; 30 of 330). The odds of engaging in
each of these behaviours was significantly higher among
participants engaging in chemsex. However, for slamsex,
only UAI was statistically significant (Table 3). Although
a low proportion of participants engaged in sex with the
highest risk of HIV transmission (i.e. sdUAI with a detect-
able viral load), the odds of having had this type of sex
in the last year were more than three times greater if a
participant engaged in chemsex than if they did not. Par-
ticipants who engaged in chemsex also reported a signifi-
cantly higher average number of casual partners than
those who did not [31.4 versus 8.1, respectively; adjusted
(mean) difference +16.4; 95% CI 12.4–20.5]; this was also
the case for those who engaged in slamsex [26.4 versus
13.6, respectively; adjusted (mean) difference +12.2; 95%
CI 0.73–23.7].
Over 40% (40.5%; 111 of 293) reported being diag-
nosed with a bacterial STI in the last year, the odds of
which were significantly higher for participants who
engaged in chemsex and slamsex than for those who
did not (Table 4). Slamsex users were also more likely
to have been diagnosed with multiple STIs in the pre-
vious year, although this association was not seen
among participants who engaged in chemsex only
(Table 4). In addition to bacterial STIs, participants who
engaged in chemsex and slamsex also had significantly
greater odds, compared with those who did not, of ever
having been diagnosed with hepatitis C [chemsex:
21.9% versus 3.57%, respectively; adjusted odds ratio
(AOR) 6.58; 95% CI 2.24–19.3; slamsex: 36.0% versus
5.96%, respectively; AOR 9.39; 95% CI 3.01–29.3],
which was reported by 9.0% (38 of 392) of participants
overall.
Discussion
Approximately one in three sexually active MSM reported
sexualized drug use (chemsex) in the past year and this
was strongly associated with self-reported STIs
29.5%
21.7%
15.8%
20.5%
11.3%
23.0%
10.1%
4.0%
6.7%
0.4% 1.1%
6.6%
0%
5%
10%
15%
20%
25%
30%
35%
40%
Any drug Mulple drugs Crystal methamphetamine GHB/GBL Ketamine Mephedrone
Chemsex Slamsex
Fig. 1 Proportion of sexually active MSM who reported engaging in chemsex and slamsex over the past three months by drug type. GHB/GBL,
gamma-hydroxybutyric acid/gamma-butyrolactone.
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(including gonorrhoea and chlamydia) and hepatitis C. It
was also associated with sexual behaviours that pose a
risk of onward HIV transmission, including high numbers
of sexual partners, and condomless sex with partners of
unknown or HIV-negative status while having a
detectable viral load. Furthermore, this study showed a
clustering of risk factors for poor health in MSM living
in London, with chemsex being more common in MSM
who were diagnosed with depression/anxiety, who
smoked, and who took other recreational drugs. This
Table 1 Profile of sexually active men who have sex with men (MSM) with HIV infection who engaged in chemsex in the UK, showing if
chemsex use varied by socio-demographic characteristics
Denominator Any chemsex Crystal meth Mephedrone GHB Ketamine
Unweighted Weighted n (%) P n (%) P n (%) P n (%) P n (%) P
Age group
18–34 years 63 6302 14 (22.1) 0.02 7 (10.9) 0.055 14 (22.1) 0.13 12 (18.4) 0.14 7 (9.4) 0.44
35–44 years 97 6883 28 (34.3) 12 (15.6) 20 (26.0) 17 (23.0) 9 (10.6)
45–54 years 146 8654 45 (35.1) 25 (21.0) 31 (25.8) 30 (24.1) 20 (14.9)
≥55 years 86 3117 15 (18.6) 10 (11.9) 10 (12.8) 8 (9.0) 5 (7.1)
Region of birth
UK 294 16875 71 (28.4) 0.11 42 (17.7) 0.27 50 (21.2) 0.13 46 (19.6) 0.33 32 (13.0) 0.43
Europe 54 4143 18 (37.1) 4 (8.9) 13 (27.8) 12 (24.4) 6 (10.6)
Africa* 8 850 1 (NA) 0 (NA) 1 (NA) 1 (NA) 0 (NA)
Other 36 3089 12 (32.7) 8 (18.9) 11 (31.4) 8 (24.3) 3 (6.4)
Education
Up to qualification
at 16 years
86 4593 17 (26.7) 0.83 9 (13.4) 0.41 10 (17.1) 0.09 7 (10.7) 0.06 8 (12.7) 0.49
Qualification at
18 years
74 4947 20 (32.2) 11 (18.8) 17 (28.8) 15 (25.4) 8 (10.6)
Undergraduate 118 8048 33 (29.7) 18 (16.6) 27 (26.6) 25 (23.6) 15 (13.3)
Postgraduate 95 6477 26 (28.3) 12 (12.8) 16 (17.6) 16 (19.0) 7 (7.8)
Other* 12 601 4 (NA) 2 (NA) 4 (NA) 2 (NA) 2 (NA)
Employment
Employed 272 18060 75 (30.0) 0.15 41 (15.9) 0.30 54 (23.1) 0.07 50 (21.0) 0.14 32 (12.6) 0.47
Unemployed 23 1750 8 (39.1) 5 (23.3) 7 (37.4) 7 (33.7) 1 (4.5)
Other† 95 4909 18 (23.8) 7 (11.7) 14 (18.5) 9 (12.9) 8 (9.6)
Living in London
No 216 11742 26 (17.7) <0.001 16 (7.4) <0.001 24 (12.8) <0.001 22 (11.4) 0.003 18 (9.0) 0.21
Yes 176 13215 66 (40.0) 38 (23.3) 51 (32.0) 45 (28.6) 23 (13.4)
Main partner
No 138 9050 36 (29.8) 0.84 22 (18.6) 0.09 27 (23.9) 0.81 28 (23.2) 0.29 9 (7.5) 0.15
Yes 246 15804 62 (29.0) 28 (13.3) 47 (22.9) 47 (19.0) 31 (13.7)
Diagnosed anxiety or depression
No 256 16321 60 (24.6) 0.02 30 (11.5) 0.005 42 (18.1) 0.01 39 (16.2) 0.03 24 (9.8) 0.06
Yes 136 8635 42 (38.8) 24 (24.0) 33 (32.2) 28 (28.6) 17 (14.2)
Current smoker
No 266 16399 58 (24.2) <0.001 29 (12.3) 0.003 40 (17.7) <0.001 37 (16.5) 0.005 20 (8.1) 0.07
Yes 123 8521 42 (38.8) 24 (22.1) 33 (31.8) 29 (28.8) 20 (17.0)
Binge drinking
Less than weekly 319 20892 83 (29.4) 0.81 44 (16.0) 0.92 59 (22.1) 0.40 54 (20.4) 0.54 38 (13.0) 0.047
Weekly or more 58 3862 17 (31.5) 9 (16.7) 15 (29.1) 13 (25.6) 3 (4.9)
Nonsexual drug use
No 186 11733 20 (13.0) <0.001 8 (5.5) <0.001 13 (8.8) <0.001 12 (7.3) <0.001 6 (3.7) <0.001
Yes 206 13223 82 (44.2) 46 (24.9) 62 (35.5) 55 (32.2) 35 (18.1)
ART status
Not on ART 36 2885 11 (35.6) 0.42 7 (20.1) 0.63 11 (35.6) 0.07 9 (26.5) 0.45 5 (13.4) 0.76
On ART 355 22061 91 (28.8) 47 (15.3) 64 (21.3) 58 (19.7) 36 (11.1)
Time since diagnosis
<2 years 28 1992 10 (45.3) 0.13 5 (22.8) 0.37 8 (41.1) 0.06 8 (32.3) 0.23 2 (9.2) 0.81
2–5 years 103 6990 24 (24.1) 13 (11.9) 20 (21.6) 20 (21.0) 11 (11.5)
6–10 years 114 8058 37 (33.8) 19 (18.9) 25 (23.4) 21 (21.6) 16 (13.2)
≥11 years 147 7917 31 (26.1) 17 (14.3) 22 (19.2) 18 (15.8) 12 (9.8)
ART, antiretroviral therapy; GHB, gamma-hydroxybutyric acid; NA, not applicable.
Percentages represent percentages of participants in that group who engaged in chemsex and are weighted values.
*Percentages omitted because of a small denominator.
†Student, carer, retired or disabled.
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clustering of risk around chemsex, affecting a young and
vulnerable group, suggests a syndemic of sexual ill
health, drug use harms, and mental illness among HIV-
positive MSM.
This was the first study of chemsex among HIV-
positive MSM to use a national probability sample and,
through weighting, has produced national estimates that
reflect the whole population of HIV-positive MSM access-
ing care in the UK. Although the overall sample size was
small and response rates relatively low, respondents were
broadly representative of MSM in the target population
[25], and thus we felt it appropriate to weight the data
Table 2 Profile of sexually active men who have sex with men (MSM) with HIV infection who engaged in slamsex in the UK*, showing if
slamsex use varied by socio-demographic characteristics
Denominator Any slamsex Crystal meth Mephedrone
Unweighted Weighted n (%) P n (%) P n (%) P
Age group
18–34 years 63 6302 6 (9.6) 0.19 2 (2.5) 0.09 5 (8.3) 0.08
35–44 years 97 6883 7 (8.9) 5 (7.0) 5 (3.6)
45–54 years 146 8654 17 (13.6) 12 (10.3) 12 (9.5)
≥55 years 86 3117 4 (4.5) 4 (4.5) 4 (19.1)
Region of birth
UK 294 16875 25 (10.8) 0.65 19 (8.5) 0.30 16 (6.6) 0.77
Europe 54 4143 6 (11.4) 2 (3.2) 3 (7.3)
Africa† 8 850 0 (NA) 0 (NA) 0 (NA)
Other 36 3089 3 (7.7) 2 (3.4) 2 (7.7)
Education
Up to qualification at 16 years 86 4593 4 (6.1) 0.45 2 (3.2) 0.42 3 (4.4) 0.60
Qualification at 18 years 74 4947 6 (11.3) 3 (5.3) 4 (8.7)
Undergraduate 118 8048 13 (12.2) 10 (8.8) 8 (7.6)
Postgraduate 95 6477 8 (8.7) 6 (6.7) 5 (4.7)
Other† 12 601 2 (NA) 1 (NA) 1 (NA)
Employment
Employed 272 18060 25 (10.3) 0.38 17 (6.8) 0.29 16 (6.5) 0.95
Unemployed 23 1750 4 (17.2) 3 (12.7) 2 (7.8)
Other‡ 95 4909 5 (7.4) 3 (4.0) 4 (6.8)
Living in London
No 216 11742 12 (6.0) 0.04 7 (3.3) 0.01 9 (4.5) 0.12
Yes 176 13215 22 (13.8) 16 (9.7) 13 (8.5)
Main partner
No 138 9050 11 (9.2) 0.53 9 (7.1) 0.44 9 (7.5) 0.61
Yes 246 15804 22 (10.3) 13 (6.1) 13 (6.3)
Diagnosed anxiety or depression
No 256 16321 19 (8.4) 0.31 11 (4.6) 0.04 13 (5.5) 0.48
Yes 136 8635 15 (13.4) 12 (10.5) 9 (8.6)
Current smoker
No 266 16399 19 (8.4) 0.15 13 (5.4) 0.32 10 (4.5) 0.03
Yes 123 8521 14 (12.8) 9 (8.4) 11 (10.0)
Binge drinking
Less than weekly 319 20892 28 (9.9) 0.94 18 (6.4) 0.53 19 (6.7) 0.22
Weekly or more 58 3862 5 (9.5) 5 (9.5) 2 (3.5)
Nonsexual drug use
No 186 11733 10 (6.9) 0.24 5 (3.3) 0.02 6 (4.5) 0.21
Yes 206 13223 24 (13.3) 18 (9.7) 16 (8.4)
ART status
Not on ART 36 2885 6 (20.2) 0.02 3 (7.5) 0.80 5 (17.4) 0.002
On ART 355 22061 28 (8.8) 20 (6.6) 17 (5.2)
Time since diagnosis
<2 years 28 1992 3 (15.9) 0.59 1 (1.5) 0.41 3 (15.9) 0.10
2–5 years 103 6990 10 (10.2) 6 (6.4) 6 (6.0)
6–10 years 114 8058 11 (10.2) 9 (8.6) 5 (4.5)
≥11 years 147 7917 10 (8.6) 7 (6.3) 8 (6.9)
ART, antiretroviral therapy; NA, not applicable.
Percentages represent percentages of participants in that group who engaged in slamsex and are weighted values.
*Data on gamma-hydroxybutyric acid (GHB) and ketamine are not presented as only two and four people, respectively, reported slamsex with them.
†Percentages omitted because of a small denominator.
‡Student, carer, retired or disabled.
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and generalize the findings to the wider population of
HIV-positive MSM accessing care. Data were collected
from people linked to NHS HIV care and therefore we
cannot extrapolate our findings beyond this group, mean-
ing that they may not be representative of the entire UK
MSM population living with HIV. People not linked to
HIV care, or who are unaware of their HIV status, may be
more likely to engage in risky sexual practices and be
more likely to transmit HIV, possibly making the esti-
mates herein conservative for the overall population
[32,33]. There was also the possibility that our estimates
of chemsex and STIs were conservative as a consequence
of social desirability bias leading to underreporting of
such behaviours. To minimize this problem, data were
collected using a web-based self-interview, which has
been found to increase disclosure of sensitive and stigma-
tized behaviour [34,35]. Importantly, the data on viral
load were not self-reported, avoiding reporting bias for
this parameter.
As with all cross-sectional studies, our findings repre-
sent associations only and we cannot be certain that
chemsex occurred at the same time as sex with a high
risk of HIV transmission, or make causal inferences, such
as stating that chemsex causes people to engage in riskier
sex. Indeed, the 1-year reference period for the measures
is a limitation of the study, with relationships between
chemsex and specific sexual practices better analysed
using sexual encounter-level data. Despite this, previous
reports from the UK have indicated that chemsex is often
associated with more sexual partners, higher HIV risk
sex, and not taking antiretroviral drugs, meaning that
there is an increased likelihood that participants would
have had a detectable viral load during their chemsex
sessions [6,9–11,13,36,37].
Irrespective of causality or the sequence of events, our
findings show that taking drugs before or during sex is
linked to a higher number of sexual partners, higher levels
of high-risk sexual behaviours, and increased STI diag-
noses, which is in line with previous findings in the UK
[13,16]. Additionally, we have highlighted that HIV-posi-
tive MSM engaged in chemsex are more likely to have
mental health issues and other addictive behaviours, and
that these risks and morbidities are occurring in the same
individuals. Attention must therefore be paid not only to
the association between chemsex, STIs, the hepatitis C
epidemic, and behaviours that are driving the HIV epi-
demic, but also to its impact on the overall health of
HIV-positive MSM. Given this potentially devastating syn-
demic, the fact that chemsex appears to be on the increase
[6,8,19,20], chemsex being linked to increases in HIV inci-
dence in MSM [9,13,21,22] and increases in STI diagnoses
in MSM [15,16], and that it can cause severe side effects
and even death [36,38,39], it is becoming ever more
important to address chemsex as a public health priority.
To address chemsex and the syndemic surrounding it,
there is a need for a joined-up response between HIV
treatment, mental health, addiction, and sexual health
services. Traditional drug dependence services, which
focus on opiate use, have had poor uptake by MSM [40],
probably because their current configuration is not suited
to addressing the needs of MSM and the sexual nature of
their drug use [9]. There is evidence that MSM who
engage in chemsex prefer to receive drug counselling
services based in sexual health clinics, which traditionally
have high attendance levels from MSM in the UK [7].
Indeed, some sexual health clinics in London are offering
focussed chemsex programmes with trained staff and
chemsex care plans for patients [7,41,42]. Although these
programmes have found high levels of acceptability and
uptake among MSM engaging in chemsex [19,36], they
remain in their infancy and their effectiveness has not
yet been fully evaluated [7,43].
Future research should therefore focus on ways of
addressing the syndemic of ill health, drug use harms,
and mental illness among HIV-positive MSM. Such
research should take a broad public health approach that
includes examining the possible social and cultural
determinants. The need for holistic approaches to health
among MSM has been emphasized in Public Health
England’s MSM strategic action plan and its commis-
sioner’s toolkit for chemsex, which highlight the interac-
tions between health, substance use, and sexual risk
behaviours [44,45]. Therefore, service evaluations and
the development and testing of a set of best-practice
guidelines for helping health care staff, including
general practitioners [38], to manage patients should be
prioritized. Developing a robust evidence base around
the wider issues surrounding chemsex and how to best
help men who are engaged in chemsex to remain safe
must be priorities going forward.
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